Amy Ganske
Family · Cedar Rapids, IANPI 1891891339
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,419 of the $3,490 with a category attached, or 69.3%. 37 manufacturers reported payments, led by Genentech USA, Inc. at 26.9% of the total. 2025 is the largest year on record at $1,466, more than ten times the $64 reported in 2021. Among family clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 97 payments — averaging $35.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$940
- Merck$268
- AstraZeneca$251
- Daiichi Sankyo Inc.$210
- Johnson & Johnson$194
- Pfizer$193
- plus $1K from 31 others
What the payments were for
- Consulting fees$90026%
- Food & beverage$2,41969%
- Education$1715%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 3 | $940 |
| Merck | 7 | $268 |
| AstraZeneca | 6 | $251 |
| Daiichi Sankyo Inc. | 7 | $210 |
| Johnson & Johnson | 8 | $194 |
| Pfizer | 8 | $193 |
| Seagen Inc. | 4 | $156 |
| Novartis | 7 | $137 |
| AbbVie | 7 | $128 |
| Array Biopharma Inc | 2 | $114 |
| Bayer | 1 | $105 |
| Jazz Pharmaceuticals Inc. | 2 | $99 |
| Bristol Myers Squibb | 4 | $80 |
| Sanofi | 3 | $65 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $64 |
| Exelixis Inc. | 3 | $55 |
| Puma Biotechnology, Inc. | 2 | $40 |
| Lilly USA, LLC | 2 | $34 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $30 |
| Janssen Scientific Affairs, LLC | 1 | $24 |
| Blueprint Medicines Corporation | 1 | $23 |
| Tersera Therapeutics LLC | 1 | $23 |
| Pharmaessentia USA Corporation | 1 | $23 |
| Gilead | 1 | $21 |
| Servier Pharmaceuticals LLC | 1 | $21 |
| Ipsen Biopharmaceuticals, Inc | 1 | $19 |
| Deciphera Pharmaceuticals Inc. | 1 | $18 |
| Beigene USA, Inc. | 1 | $18 |
| Incyte Corporation | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Tempus AI, Inc | 1 | $16 |
| CTI Biopharma Corp. | 1 | $15 |
| Taiho Oncology, Inc. | 1 | $15 |
| Beone Medicines USA, Inc. | 1 | $15 |
| AVEO Pharmaceuticals, Inc. | 1 | $14 |
| Coherus Oncology, Inc. | 1 | $14 |
| Novocure Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,490 in reported general payments places this provider in the 95th percentile of 1,268 family providers in Iowa.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 35 | $548,786 |
| KisqaliRibociclib Succinate | 14 | $215,779 |
| EliquisApixaban | 18 | $10,704 |
| Exemestane | 41 | $2,830 |
| Anastrozole | 178 | $2,434 |
| Ondansetron Hcl | 106 | $1,496 |
| Gabapentin | 125 | $1,356 |
| Potassium Chloride | 46 | $711 |
| Fluconazole | 15 | $517 |
| Dexamethasone | 26 | $466 |
| Acyclovir | 45 | $409 |
| Lorazepam | 32 | $227 |
| Levofloxacin | 29 | $203 |
| Duloxetine Hcl | 28 | $181 |
| Tramadol Hcl | 30 | $155 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis | $193 | $559,49053 claims |
| NovartisKisqali | $137 | $215,77914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,268 family providers in Iowa.
Other family in Cedar Rapids
- Kristen BellCedar Rapids$9K
- Sara ButlerCedar Rapids$6K
- Robert LancasterCedar Rapids$6K
- Frankie DunbarCedar Rapids$4K
- Nicole SporrerCedar Rapids$4K
- Stefanie GaticaAnkeny$354K
- Aubrey MolgaardAmes$238K
- Joan KittenFort Dodge$85K
- Megan FergusonPella$82K
- Rodney ClarkDes Moines$63K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.